Want to see PEPG full AI Analyst Report?
PEPG Stock Chart & Stats
$3.08
-$0.17(-8.10%)
At close: 4:00 PM EDT
$3.08
-$0.17(-8.10%)
Day’s Range― - ―
52-Week Range$1.31 - $7.80
Previous CloseN/A
Volume735.00K
Average Volume (3M)840.41K
Market Cap
$198.77M
Enterprise Value$23.42M
Total Cash (Recent Filing)$117.24M
Total Debt (Recent Filing)$16.09M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 10, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding69,259,514
10 Day Avg. Volume770,316
30 Day Avg. Volume840,411
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.65
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$11.75Price Target Upside281.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementAdvancement into higher-dose Phase 2 cohorts and completion of enrollment in the 10 mg/kg group indicate continued clinical execution. Upcoming data milestones and planned regulatory engagement could strengthen the pipeline’s strategic value if results support further development.
Liquidity RunwayCash sufficient to support operations into the fourth quarter of 2027 gives PepGen time to generate clinical data without an immediate financing requirement. That runway improves its ability to advance programs and reach important development milestones.
Improving Operating TrajectoryAlthough PepGen remains cash-burning, the reduction in operating outflow from earlier periods and narrower TTM losses suggest some improvement in cost control. Sustaining this trajectory could extend liquidity and make future funding needs more manageable.
Bears Say
No Commercial RevenueZero reported revenue confirms that PepGen has not yet established a commercial product or recurring sales base. The company therefore depends on successful clinical development and eventual commercialization to create operating revenue and support long-term business sustainability.
Persistent Losses And Cash BurnLarge recurring losses and negative operating and free cash flow show that the business is not self-funding. Continued investment in development will require substantial capital, leaving performance and strategic flexibility exposed to future financing requirements.
Eroding Capital BaseDeclining equity indicates that accumulated operating losses are reducing the company’s capital base despite manageable debt. If losses continue, PepGen may have less balance-sheet capacity to absorb setbacks or fund development without additional capital.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.31 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $198.77M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 10, 2027 which is in 140 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.284 by $0.024.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,259,514 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.284. Following the earnings report the stock price went up 21.717%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.75 (281.49% Upside)
$11.75 (281.49% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.02%
12-Months-Change
Fundamentals
Return on Equity
-51.01%
Trailing 12-Months
Asset Growth
38.30%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$11.75
▲(281.49% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
29.84% Insiders
3.69% Mutual Funds
57.14% Other Institutional Investors
5.18% Public Companies and
Individual Investors